Roche to present 45 abstracts at ARVO

Immune-retina conferences can look like marketing theater. But ARVO still matters, because this is where drugmakers show the messy details doctors actually use — how often patients needed injections, how dry the retina stayed, and whether real-world clinics got the same results as trials. Roche’s update this week is basically a signal flare that it wants to keep control of that conversation in retinal disease. It said it will bring more than 45 abstracts to the ARVO annual meeting in Denver on May 3–7, 2026, including 20 oral presentations across five retinal conditions, with Vabysmo, Susvimo, and the IL-6 inhibitor vamikibart doing most of the work. (roche.com) ### Why is ARVO the place people care about? ARVO is not where a drug gets approved. It is where retina specialists pressure-test what approval actually means in practice. A company can say a medicine works, but doctors want to know what happens outside a clean phase 3 trial — in mixed clinics, in previously treated patients, and in imaging datasets that reflect real life rather than ideal enrollment rules. That is why Roche is leaning so hard on “real-world” language in this package. (roche.com) ### What is Roche actually bringing? The headline number is more than 45 abstracts, but the sharper detail is the 20 oral presentations. Oral slots matter because they are scarcer and usually get more attention than posters. Roche says the program spans geographic atrophy, retinal vein occlusion, uveitic macular edema, diabetic macular edema, and neovascular age-related macular degeneration. That spread tells you this is not a one-drug victory lap — it is a portfolio defense. (roche.com) ### Why does Vabysmo sit at the center? Because Vabysmo is Roche’s main retina growth engine, and the company is still trying to widen the gap between “works” and “works with less treatment burden.” The new ARVO package highlights six-month real-world VOYAGER data in wet AMD and DME showing retinal drying and improved anatomy, including in both treatment-naive patients and people who had already used other anti-VEGF drugs. Roche also says those analyses used deep-learning review of OCT images, which is a way to make a giant real-world imaging set more usable and more standardized. (roche.com) ### Why are people zeroing in on RVO? Because retinal vein occlusion is where durability still really matters. Patients often need frequent injections, so even modest interval gains can change clinic flow and patient burden. Roche has not yet blasted out a splashy new interval number in the main press release, but it did flag fresh Vabysmo RVO presentations, and Roche’s ARVO science hub lists two real-world RVO sessions on May 3 — one from the IRIS Registry and one from the UK FARWIDE-RVO study. That means the market is likely about to get practice-level evidence, not just another recap of the old trials. (roche.com) ### What about Susvimo? Susvimo is the other important piece because it attacks treatment burden from a different angle — continuous drug delivery instead of stretching injection intervals. Roche says the ARVO data will focus on sustained disease control with fewer treatment visits. So the company is showing two competing ideas at once: longer-acting injections with Vabysmo, and implanted continuous delivery with Susvimo. That is useful strategically, because retina doctors do not all want the same kind of convenience. (roche.com) ### And vamikibart? That is the earlier-stage bet. Vamikibart targets IL-6, which means inflammation rather than the VEGF pathway that dominates current retinal treatment. Early ARVO data will not settle its future, but Roche is clearly trying to show it has something beyond the current anti-VEGF cycle. In plain English — it wants investors and doctors to see a next act, not just line extensions. (roche.com) ### So what should clinics watch for next week? Watch the RVO readouts first, then the real-world Vabysmo anatomy data, then any signs that Susvimo is regaining momentum as a burden-reduction option. The key question is not whether Roche has enough abstracts. It does. The key question is whether the ARVO details make retina specialists more confident that these therapies hold up in ordinary practice — where dosing intervals, visit load, and imaging outcomes decide what gets used. (roche.com)